Prevalence and clinical characteristics of CMV coinfection among HIV infected individuals in Guinea-Bissau:a cross-sectional study by Grønborg, Helene L et al.
 
  
 
Aalborg Universitet
Prevalence and clinical characteristics of CMV coinfection among HIV infected
individuals in Guinea-Bissau
a cross-sectional study
Grønborg, Helene L; Jespersen, Sanne; Egedal, Johanne H; Correia, Faustino G; Medina,
Candida; Krarup, Henrik; Hønge, Bo L; Wejse, Christian; Bissau HIV Cohort study group
Published in:
Tropical Medicine & International Health
DOI (link to publication from Publisher):
10.1111/tmi.13082
Publication date:
2018
Document Version
Accepted author manuscript, peer reviewed version
Link to publication from Aalborg University
Citation for published version (APA):
Grønborg, H. L., Jespersen, S., Egedal, J. H., Correia, F. G., Medina, C., Krarup, H., Hønge, B. L., Wejse, C., &
Bissau HIV Cohort study group (2018). Prevalence and clinical characteristics of CMV coinfection among HIV
infected individuals in Guinea-Bissau: a cross-sectional study. Tropical Medicine & International Health, 23(8),
896–904. https://doi.org/10.1111/tmi.13082
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
A
cc
ep
te
d
 A
rt
ic
le
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/tmi.13082 
This article is protected by copyright. All rights reserved. 
Article Type: Original Article 
 
Prevalence and clinical characteristics of CMV coinfection among HIV infected individuals in 
Guinea-Bissau: A cross-sectional study 
 
Helene L. Grønborg1,2, Sanne Jespersen2,3, Johanne H. Egedal4, Faustino G. Correia2,5, Candida 
Medina5, Henrik Krarup6, Bo L. Hønge2,5,7, Christian Wejse1,2,3, for the Bissau HIV Cohort study group1 
 
1 GloHAU, Department of Public Health, Aarhus University, Aarhus, Denmark 
2 Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau 
3 Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark 
4 Institute of Biomedicine, Aarhus University, Aarhus, Denmark 
5 National HIV Programme, Ministry of Health, Bissau, Guinea-Bissau 
6 Section of Molecular Diagnostics, Clinical Biochemistry, Aalborg University Hospital, 9100 Aalborg, 
Denmark 
7 Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark 
 
ABSTRACT 
Objectives: To describe the prevalence of CMV in a cohort of HIV infected individuals in Guinea-
Bissau, West Africa and to evaluate differences in patients’ clinical characteristics associated with 
their CMV status.  
Methods: Newly diagnosed HIV infected adults were invited to participate in this cross-sectional 
study, from May until December 2015. Enrolled patients were interviewed and underwent a full 
physical examination focusing on CMV disease manifestations. Blood samples were analyzed for 
CMV serology, QuantiFERON-CMV response and CMV DNA. Mortality follow-up were registered for 
one year after inclusion. 
Results: In total, 180 patients were enrolled. Anti-CMV IgG positivity was found in 138/138 (100%) 
and 4/138 (2.8%) were anti-CMV IgM positive. A positive QuantiFERON-CMV response was found in 
60/70 (85.7%) of the patients and 83/137 (60.6%) had CMV viremia. QuantiFERON-CMV response 
and detectable CMV DNA were associated with lower CD4 cell count, older age, and upper 
gastrointestinal complaints. During one year of follow-up, the IRR for death among CMV DNA 
                                                          
1
 The Bissau HIV cohort study group comprises: Amabelia Rodrigues, David da Silva, Zacarias da Silva, Candida Medina, 
Ines Oliviera-Souto, Lars Østergaard, Alex Laursen, Christian Wejse, Peter Aaby, Anders Fomsgaard, Christian Erikstrup, Bo 
L. Hønge, and Sanne Jespersen (chair).  
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positive patients was 1.5 (p=0.5). 
Conclusions: CMV coinfection was detected among all enrolled patients and CMV viremia was highly 
prevalent. Only age and upper gastrointestinal complaints were associated with the patients’ CMV 
status. 
 
Keywords: Clinical characteristics; Cytomegalovirus; Guinea-Bissau; HIV; Mortality; CMV prevalence 
 
INTRODUCTION 
Approximately 37 million people are infected with human immunodeficiency virus (HIV) worldwide 
(1). The majority of this burden is borne in sub-Saharan Africa, where 74% of HIV-associated deaths 
occur (2). There are two types of HIV: HIV type 1 (HIV-1) and HIV type 2 (HIV-2), the latter mainly 
restricted to West Africa (3-5). Compared with HIV-1, HIV-2 is less transmissible and is associated 
with a lower viral load and a slower rate of CD4 cell count decline (6). The West African country 
Guinea-Bissau has experienced a stabilization in HIV-1 prevalence (4.0%), and still holds the world´s 
highest prevalence of HIV-2 (2.8%), although it is decreasing (7). 
 Cytomegalovirus (CMV) establishes latent infections, mainly in leukocytes and their progenitor 
cells, and has a suppressive effect on the immune system (8, 9). In immunosuppressed individuals, 
such as HIV infected individuals with advanced disease progression, the risk of CMV disease is high, 
with possible symptoms ranging from short-limiting febrile periods to severe end-organ disease 
(EOD) (10). The degree of immunosuppression correlates with the risk of symptomatic disease, 
which is particularly increased if the CD4 cell count drops below 100 cells/µl (11). Retinitis and colitis 
are the most frequent CMV manifestations worldwide (12). In addition to causing EOD, increasing 
evidence suggests that CMV has an indirect effect on HIV by enhancing HIV transmission and 
progression with subsequent increased mortality, despite antiretroviral treatment (ART) (13).  
 CMV seroprevalence is known to range from about 50% in the general adult population in high-
income countries (10), to more than 80% in low-income countries (14, 15). Among high risk groups, 
such as men who have sex with men and individuals infected with HIV, the seroprevalence is more 
than 80% in both high- and low-income countries (16, 17). However, studies carried out in West 
Africa have revealed CMV seroprevalences as low as 56% in some HIV infected study populations 
(13). Considering the varying prevalences of CMV infection reported in West Africa, and the high risk 
of reactivation among HIV-infected individuals with advanced disease, we aimed to investigate CMV 
coinfection and associated clinical characteristics in a well-characterized HIV cohort in Guinea-Bissau 
(18, 19).  
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METHODS 
Setting 
Hospital Nacional Simão Mendes (HNSM) is the main hospital in the capital Bissau, and houses the 
largest HIV outpatient clinic in Guinea-Bissau in terms of patients on follow-up. In 2007, the Bissau 
HIV Cohort was established, and since then information about the patients’ clinical and biochemical 
status have been registered continuously (19). 
 
Design and Study population 
This study was a cross-sectional sample of a prospective cohort. Main data presented are the 
baseline CMV data retrieved as a cross-sectional study. However, follow-up data on mortality were 
retrieved as a longitudinal cohort study.  
 The study was conducted at the HIV outpatient clinic at HNSM from 26th of May until 10th of 
December 2015. All newly diagnosed HIV infected individuals over 15 years of age were eligible for 
enrollment. People who did not speak Portuguese Creole and patients who had already started ART 
elsewhere were excluded from participation.  
 All included patients were interviewed for symptoms of CMV EOD. Further, a physical 
examination including full neurological examination and ophthalmoscopy with tropicamide-induced 
mydriasis (Mydriacyl 1%, Alcon, Fort Worth, Texas, USA) was performed. Before starting ART and 
within one month of the initial examination, whole blood samples (5 mL) were collected. 
 One person performed all ophthalmoscopies. The ophtalmoscopist received structured training 
in the procedure. Abnormal ophthalmoscopy findings were not classified to be CMV retinitis or other 
due to limited experience.  
 The main focus of the clinical interview and physical examination were symptoms suggestive of 
CMV EOD: 
- Ophthalmoscopy findings compatible with CMV retinitis +/- vision problems (eye pain, vision 
loss, scotomas or floaters) 
- Palpable hepatomegaly +/- gastrointestinal complaints (odynophagia, dysphagia, retrosternal 
pain, stomach pain, melena and/or hematochezia) 
- Abnormal neurological findings +/- complaints compatible with encephalitis or radiculopathy 
(headaches, confusion, change in memory function, numbness, pain in legs, change in ability to walk, 
urine retention and/or reduction of sensibility in legs) 
 Mortality follow-up on patients was done until death or censoring at 365 days from inclusion. If 
transferred to other clinics or lost to follow-up (LTFU) they were censored at time of transferal or at 
last visit at the clinic (if lost). Patients on ART who did not return to the clinic for more than 6 month 
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were presumed LFTU.  
 
Laboratory methods 
HIV screening was done using Alere Determine HIV-1/2 assays (Alere Ltd., Stockport, UK) or SD 
Bioline HIV Ag/Ab Combo (Standard Diagnostics, Yongin-si, Republic of Korea) at the HIV outpatient 
clinic. Discrimination of HIV types was done by SD Bioline HIV 1/2 3.0 (Standard Diagnostics, Yongin-
si, Korea) or ImmunoComb HIV 1/2 BiSpot (Organics, Yavne, Israel).  At times Bioline HIV1/2 3.0 was 
not available at the clinic, causing a lack in discrimination of HIV type among the patients included in 
these periods. When the test became available we invited the patients to get tested. However, a 
large proportion of patients did not return to the clinic. CD4 cell count was measured at the national 
reference laboratory in Bissau, using the Partec CyFlow SL_3 flowcytometer (CyFlow SL, Partrc, 
Munster, Germany).  
 For CMV serology whole blood samples were collected and prepared for storage at the national 
reference laboratory in Bissau. Plasma samples were frozen until tested for IgG and IgM antibody 
responses specific to CMV at Department of Clinical Immunology, Aarhus University Hospital, 
Denmark, using ARCHITECT CMV IgG and IgM chemiluminescence assays (Abbott Laboratories, 
Abbott Park, IL, USA). Responses were interpreted as reactive, non-reactive or grayzone according to 
levels set by the manufacturer (20, 21). 
 Cellular immunity against CMV was determined by detection of IFN-γ following ex-vivo 
stimulation with CD8 T-cell specific CMV antigens. Whole blood was collected in three specialized 
QuantiFERON-CMV (QF-CMV) collection tubes (Cellestis, QIAGEN, Chadstone, Australia). IFN-γ levels 
(IU/mL) were measured using Human IFN gamma ELISA Ready-Set-Go! (eBioscience, Santa Clara, 
California, USA), at the Institute of Biomedicine, Aarhus University, Denmark. The QF-CMV responses 
were interpreted as reactive, non-reactive or indeterminate according to IFN-γ levels set by the 
manufacturer (22). 
For CMV virology CMV-DNA in plasma samples was quantified using the Abbott CMV RealTime assay 
on the Abbott m2000 platform (Abbott Laboratories, Illinois, USA), at Section of Molecular 
Diagnostics, Clinical Biochemistry, Aalborg University Hospital (23). The limit of quantification was 20 
copies/mL.  
 In this article ‘CMV status’ refers to all three biomarkers; CMV DNA, CMV antibodies and CMV 
INF- γ response. If concerning one specific biomarker, it is specified.  
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Statistical methods 
All data were entered in an Access database (Microsoft Corporation, Redmond, Washington, USA).  
Statistical analyses were performed using Stata IC 13.0 (StataCorp, College Station, Texas, USA). For 
categorical variables a Chi-square test was used. Logistic regression analysis was used to evaluate 
clinical characteristics associated with CMV status in the Chi-squared test for adjustment of sex, age 
and CD4 cell count. Mortality analysis was done using poisson regressions-analysis. A p-value <0.05 
was considered significant. In case of multiple comparisons the Bonferroni correction was used to 
adjust significance level. When specific data on a patient was missing, the individual was excluded 
from the specific analysis. 
 
Ethical considerations 
The study protocol was reviewed by The National Research Ethics Committee of Denmark, and 
received a consultative approval in April 2015 (case number 1500122). The study protocol was 
reviewed and approved by the National Ethical Committee of Guinea-Bissau in May 2015 
(0014/CNES/INASA/2015). Written consent, or fingerprint in case of illiteracy, was given by all 
patients before enrollment in the study.  
 
RESULTS 
Study population 
We enrolled 180 patients (Figure 1). Of these, 64.4% (116/180) were female, 35.6% (64/180) were 
male. The age range was 20 to 66 years, with a mean age of 38.6 years. Distribution of HIV types 
showed 69.4% (125/180) were infected with HIV-1, 9.4% (17/180) with HIV-2, 4.4% (8/180) with HIV-
1/2, and 16.7% (30/180) did not have HIV type determined. Of the 180 persons included in this 
study, 147 patients returned to the clinic for CD4 cell count during the study period. CD4 cell counts 
ranged from 8 to 1140 cells/µL, with a median of 198 cells/µL (IQR 100-404). An illustration of 
number of patients included in the different blood analysis is given in Figure 2.  
 
CMV antibody status 
Of the 147 patients returning to the clinic, 138 gave a blood sample for CMV antibody testing. We 
found a 100.0% (138/138) anti-CMV IgG positivity and a 2.8% (4/138) anti-CMV IgM positivity (four 
patients, one of which was found to be in a grayzone). No significant differences in clinical 
characteristics (sex, age, CD4 cell count or HIV type), were found between the 42 patients who did 
not return to the clinic for blood sampling, compared with the patients who had their blood tested 
by serology.  
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CMV QuantiFERON status 
A limited number of QF-CMV assays (n=71) became available at the clinic during this study, and 
patients were enrolled for QF-CMV testing consecutively at that point. CMV reactivity was found in 
85.7% (60/70) of the patients, and one sample was considered indeterminate. The IFN-γ response 
ranged from zero to 10,219.8 IU/mL, and among the reactive samples a median of 586.9 IU/mL (IQR 
56.1-2,208.3) was found. Compared to patients not examined by QF-CMV, we did not find any 
significant differences in clinical characteristics.   
 There were no significant differences in sex, age, HIV-type or CD4 cell count, between QF-CMV 
reactive and non-reactive HIV patients. Nor was there any significant correlation between QF-CMV 
response values and CD4 cell count. However, when comparing the reactive QF-CMV response 
values with age, a significant positive correlation was found (r2=0.07, regression coefficient (β) =60.7, 
p=0.05) (Figure 3). When adjusting for CD4 cell count and CMV viral load, the correlation was even 
more pronounced (r2=0.11, β=74.1, p=0.02). 
 
CMV viremia status  
Of the plasma samples tested for CMV viremia, CMV DNA was detected in 60.6% (83/137) of the 
samples, with viral load ranging from <20-80.000 copies/mL. A quantitative result (>20 copies/mL) 
was found in 53 samples, with a median of 120 copies/mL (IQR 35-280) in these 53 patients.  
 Older age and lower CD4 cell count were both found significantly associated with CMV viremia 
in patients with detectable CMV DNA compared with patients with undetectable CMV DNA (p=0.02 
and p<0.01 respectively) (Table 1). However, the associations did not remain significant when 
stratifying by CMV viral load, or when using regression analysis. No significant associations between 
CMV viremia and sex, HIV type or QF-CMV response were found. 
 
Demographic data and clinical characteristics by CMV status 
By comparing CMV IFN-γ reactivity and CMV DNA levels with clinical characteristics found at 
inclusion, and with demographic data, only few associations were found. Self-reported odynophagia 
and dysphagia were found among 30.0% (21/70) and 31.4% (22/70) of the patients tested by the QF-
CMV assay, and these symptoms were twice as frequent among patients with high QF-CMV response 
and significantly associated with QF-CMV strata (p=0.04 and p=0.02 respectively) (Table 2). 
Furthermore, 35 patients (n=175) had oral thrush, which were also correlated to odynophagia 
(p=0.05). No other symptoms, neither self-reported nor found during physical examination, were 
associated with CMV status. 
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 With regard to CMV retinitis, 41.2% (153/180) of the patients who were examined by 
ophthalmoscopy claimed to suffer from self-reported floaters and/or scotomas. Yet, only 12.4% 
(19/153) had unspecified abnormal ophthalmoscopy findings, and only 7.3% (11/150) had vision 
field deficiencies at the physical examination. However, we did find a significant association between 
the unspecified abnormal ophthalmoscopy findings and self-reported eye-pain (p<0.01), but no 
associations between ophthalmoscopy findings and QF-CMV or CMV DNA status were found. We did 
not find any significant differences in clinical characteristics, when comparing the patients who had 
ophthalmoscopy performed with the patients who declined the examination.  
 When analyzing a subpopulation, with CD4 cell counts below 100 cell/µL (n=31), self-reported 
epigastric pain was significantly associated with higher CMV DNA strata (p=0.05) (NS Bonferroni). 
When limiting the population further, to CD4 cell count below 50 cells/µL (n=14), we also found self-
reported retrosternal- and umbilical pain to be significantly associated with higher CMV DNA strata 
(p=0.05 and p=0.02 respectively, data not shown) (NS Bonferroni). 
 
Follow-up analysis 
The CMV DNA tested patients (n=137) was followed one year regarding survival, giving 95.8 person 
years of follow-up time. During this period 112 (81.8%) started ART. In total, 10 patients died during 
follow-up, six during ART treatment, four before initiation of ART. The overall incidence rate (IR) for 
death was 10.4 deaths per 100 person-years. IR for death among CMV DNA positive patients was 
13.9 deaths per 100 person-years. Among the CMV DNA negative patients the IR for death was 5.2 
deaths per 100 person-years. The incidence rate ratio (IRR) for death was 1.5 among CMV DNA 
positive patients compared with CMV DNA negative patients, however not significant (p=0.5). When 
only looking at patient with viremia >1000 copies/mL (n=4) compared with patients without CMV 
viremia (n=54), the IRR for death increased to 3.4, however not significantly (p=0.3). 
 During follow-up eight of the CMV DNA tested patients were transferred to other health centers 
and 45 patients were LTFU. Regarding the clinical characteristics of patients LTFU, we did not find 
any significant differences compared with patients not LTFU, except CD4 cell count. We performed a 
sensitivity analysis and assumed all patients LTFU to be dead. The IRR for death was 1.0 (p=1.0) 
among CMV DNA positive patients compared with CMV DNA negative patients. 
 
DISCUSSION 
This study is the first to report CMV prevalence in Guinea-Bissau. Among newly diagnosed HIV 
infected adults, CMV was highly prevalent with a 100% IgG reactivity specific to CMV, and a 2.8% 
IgM reactivity specific to CMV. A positive QF-CMV test for IFN-γ response was found in 85.7% of the 
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patients, and 60.6% of the patients had CMV viremia at time of HIV diagnosis.  
 This study has certain limitations. Primarily, IgG level measurements were only semi-
quantitative, stated by the manufacturer of ARCHITECT (20), causing us not to examine the serology 
results in relation to any clinical characteristics. Furthermore, a subgroup of the study population did 
not supply a blood sample. However, their clinical characteristics were not significantly different 
from the CMV serology-tested patients, which also previously has been shown in the Bissau HIV 
cohort (24). Thus, it is unlikely that they have caused a selection bias. The low median CD4 cell count 
in this study population could possibly have caused confounding errors; patients could be suffering 
from other co- or superinfections. Consequently, the findings from the physical examination or the 
self-reported symptoms may have had other causes than CMV coinfection. Ideally, this study would 
have had an HIV negative control group, and additionally a complete diagnostic set-up. However, it 
was not possible to obtain definite CMV EOD diagnosis in our setting, due to the complexity of the 
diagnostic procedures including biopsies and fundoscopies. Lastly, it has previously been shown that 
the discriminatory HIV tests used at the national HIV clinic in Bissau have low discriminatory 
capacity, causing HIV type misclassifications (25). This may have interfered with our results, giving a 
falsely high number of HIV-1/2 infected individuals, and it seems mainly to be the HIV-2 infected 
who is misclassified.  
 A strength of this study is that we only included ART-naïve HIV-infected individuals, which 
reduces the risk of ART affecting of our results, as it reduces CMV viremia (11, 26). Also, to our 
knowledge, the clinical characteristics and prevalence of CMV and HIV coinfection have only been 
investigated to a limited extent concerning HIV-2 (13). Interestingly, CMV EOD were significantly 
more frequent among HIV-2 infected individuals than HIV-1 and HIV-1/2 infected individuals in an 
autopsy study (27), yet we were not able to identify any correlation between HIV type and CMV 
status in this study. The number of HIV2 and HIV1/2 infected patients included in this study was too 
small to provide sufficient power to detect any associations with CMV status. Third, we are the first 
to use the QF-CMV assay in a large HIV population in a resource-limited setting. Our exhaustive 
examination of symptoms suggestive of CMV EOD is also unpreceded, with previous studies mainly 
focusing on CMV biomarkers and mortality rates. Eight studies across Africa have investigated HIV 
and CMV coinfection associated mortality (13). All found similar results: HIV-1-infected patients with 
CMV viremia had higher mortality risk. In this study, the IRR for death among CMV DNA positive 
patients was 1.5, however not significant (p=0.5). This may be due to a relatively small number of 
included patients, few registered deaths, and a high frequency of LTFU. Also, a CMV viral load of 120 
copies/mL is considered a low level of viremia (28, 29), and it is possible that the lower CMV viral 
loads have diluted any increased risk of death in patients with higher viremia. The fact that most 
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved. 
patients started ART shortly after inclusion probably even further diminished the chance of finding 
any increased risk of death, as ART is known to reduce CMV viral loads.  
 Due to previous studies showing a high mortality rate among patients LTFU (30, 31) we 
performed a sensitivity analysis assuming all patients LTFU to be dead. However, no significant IRR 
for death appeared. We only found the patients LTFU to significantly differ in CD4 cell count 
comparing clinical characteristics with patients not LTFU, which is in consistency with previously 
findings (32). 
 CMV is known to be highly prevalent in resource-limited settings worldwide (33), consistent 
with our findings. Using the QF-CMV assay, we found a significant correlation with age, which 
indicates a higher ability of CMV IFN-γ production with age, independent of CD4 cell count and CMV 
viral load, perhaps due to longer CMV exposure time. Also, self-reported odynophagia and dysphagia 
were associated with patients’ QF-CMV responses. This may indicate an association between 
infection in the upper gastrointestinal tract and CMV-specific IFN- γ production. However, the main 
reason for upper gastrointestinal complaints in HIV infected individuals is known to be esophageal 
candidiasis (34), which is consistent with our findings of a significant correlation between oral thrush 
and odynophagia. There are only three other studies using QF-CMV assay on HIV infected individuals 
(35-37), none of which report on clinical symptoms, hence we could not compare these results with 
other studies.  
 We showed CMV viremia to be highly prevalent and significantly associated to both age and CD4 
strata. Yet, the findings did not remain significant in a regression analysis. Other studies in African 
settings have found CMV viremia in HIV infected adults less prevalent, with detection of CMV 
viremia among 2-23% (13). This may be an expression of an unexplained high prevalence of active 
CMV infection in our cohort, possibly combined with a high quality PCR analysis conducted in 
Denmark. The relatively low CD4 cell counts possibly also affect the prevalence of CMV viremia in 
our population. However, the Tanzanian study describing the second highest prevalence of CMV 
viremia at 22.6% (14), was conducted on a population with a median CD4 cell count comparable to 
ours at 205 (IQR 79-403) cell/µL.  
 Self-reported symptoms were often not backed by objective findings during the physical 
examination, and only few correlations to CMV status were found. Comparison of unspecified 
abnormal ophthalmoscopy findings and self-reported eye pain did show a significant association, but 
there was no association between ophthalmoscopy findings and CMV status. The lack of associations 
between clinical characteristics and CMV status in this study may be due to relatively low CMV viral 
loads, and CD4 cell counts above 100 cells/µL, which reduce the risk of CMV EOD development. 
Using subgroups with CD4 cell counts below 100 and 50 cells/µL revealed a few more associations, 
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between CMV DNA and gastrointestinal complaints. A Danish study has shown CMV DNA detection 
to be predictive of the development of CMV disease with an odds ratio at 30, in an HIV-infected 
population with a median CD4 cell count of 34 cells/µL at inclusion (38). Thus one could expect a 
high frequency of CMV disease development in our study population. However, the high mortality 
rate previously described in the Bissau HIV Cohort (39), may cause patients not to survive their 
illness long enough to develop CMV EOD, as suggested in other CMV studies (40). With regard to 
diagnosis of CMV EOD in Africa, underdiagnosing is likely to be common, as multiple autopsy studies 
have found pre-mortem undiagnosed CMV EOD (41, 42). Also, the positive predictive value of CMV 
serology and virology have been found to be low (43, 44), but are still the most accessible diagnostic 
tool in many resource-limited settings. Finally, it should be mentioned that for unknown reasons, 
CMV retinitis is less commonly found in Africa than other parts of the world (40).  
 In conclusion, CMV coinfection was highly prevalent among newly diagnosed adult HIV-infected 
patients in Guinea-Bissau. This CMV coinfected HIV study population had multiple symptoms 
compatible with CMV EODs and low CD4 cell count at time of HIV diagnosis. However, only few 
correlations between clinical characteristics and CMV status were found. New and more accessible 
diagnostic tools or indicators of CMV EOD are needed, as evaluation of CMV EOD in resource-limited 
settings currently is difficult. 
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CMV DNA 
undetectable 
n (%) 
CMV DNA 
detectable 
n (%) 
 
 
p-value 
TABLE 1: Clinical characteristics of included HIV 
infected patients, stratified according to CMV 
DNA status, using chi-square test for comparison 
of groups. 
 
CMV DNA 
undetectable 
n (%) 
CMV DNA 
detectable 
n (%) 
 
 
p-value 
Sex, n 54 83 0.85 
Female 36 (66.7) 54 (65.1)  
Male 18 (33.3) 29 (34.9)  
Age (years), n 54 83 0.02 
18-30 12 (22.2) 21 (25.3)  
31-45 35 (64.8) 34 (41.0)  
46-60 7 (13.0) 26 (31.3)  
>61 0 (0.0) 2 (2.4)  
HIV type, n 46 74 0.83 
HIV-1 39 (84.8) 60 (81.1)  
HIV-2 5 (10.9) 9 (12.2)  
HIV-1/2 2 (4.4) 5 (6.8)  
CD4 cell count 
(cell/µL), n 
50 83 <0.01 
0-200 22 (44.0) 44 (53.0)  
201-350 2 (4.0) 19 (22.9)  
351-500 10 (20.0) 10 (12.1)  
500-max 16 (32.0) 10 (12.1)  
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Low1 QF-CMV 
response 
n (%) 
High2 QF-CMV 
response 
n (%) 
 
 
p-value 
TABLE 2: Clinical characteristics of patients, stratified 
according to QuantiFERON-CMV response. 
 
Low1 QF-CMV 
response 
n (%) 
High2 QF-CMV 
response 
n (%) 
 
 
p-value 
Odynophagia*, n 29 31 0.04 
No 23 (79.3) 17 (54.8)  
Yes 6 (20.7) 14 (45.3)  
Dysphagia*, n 29  31 0.02 
No 23 (79.3) 16 (51.6)  
Yes 6 (20.7) 15 (48.4)  
 
*Self-reported, 1Low response: 0.2-500 IU/mL, 2High response: 501-
max IU/mL 
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